Novus Biologicals and SDIX Form Exclusive Partnership to Create and Disseminate Premade GAT Antibodies

LITTLETON, Colo. & NEWARK, Del.--(BUSINESS WIRE)--Novus Biologicals, LLC and SDIX™ (Strategic Diagnostics Inc. d/b/a SDIX, NASDAQ: SDIX), announced today they have entered into an exclusive partnership for the creation and dissemination of premade Genomic Antibody Technology™ (GAT)™ polyclonal antibodies. Initial commercial efforts will focus on Novus’ dissemination of over 800 antibodies from SDIX’s premade collection of cancer antigen polyclonal antibodies and the creation of additional novel antibodies through the application of GAT to targets selected by Novus for inclusion in Novus’ catalog offering.